Oppenheimer Forecasts Strong Price Appreciation for Savara (NASDAQ:SVRA) Stock

Savara (NASDAQ:SVRA) had its price objective hoisted by research analysts at Oppenheimer from $8.00 to $9.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Oppenheimer’s target price indicates a potential upside of 108.57% from the company’s previous close.

SVRA has been the topic of a number of other research reports. JMP Securities upped their target price on Savara from $8.00 to $11.00 and gave the stock a “market outperform” rating in a research note on Thursday, October 23rd. Citigroup reissued an “outperform” rating on shares of Savara in a report on Thursday, October 23rd. Citizens Jmp decreased their price objective on shares of Savara from $11.00 to $10.00 and set a “market outperform” rating for the company in a research report on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of Savara in a research report on Wednesday, October 8th. Finally, Guggenheim increased their price target on Savara from $8.00 to $11.00 and gave the stock a “buy” rating in a research report on Tuesday, September 9th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Savara has a consensus rating of “Moderate Buy” and a consensus price target of $8.29.

Savara Stock Performance

NASDAQ SVRA traded up $0.06 on Friday, hitting $4.32. 634,179 shares of the company’s stock traded hands, compared to its average volume of 1,326,185. The firm’s 50-day moving average price is $3.79 and its two-hundred day moving average price is $3.06. The firm has a market capitalization of $745.79 million, a PE ratio of -8.63 and a beta of 0.45. The company has a current ratio of 11.08, a quick ratio of 11.08 and a debt-to-equity ratio of 0.25. Savara has a 1-year low of $1.89 and a 1-year high of $4.51.

Savara (NASDAQ:SVRA) last issued its earnings results on Wednesday, November 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.01). As a group, analysts expect that Savara will post -0.45 EPS for the current year.

Institutional Trading of Savara

Several institutional investors and hedge funds have recently bought and sold shares of SVRA. VR Adviser LLC boosted its stake in Savara by 172.7% during the second quarter. VR Adviser LLC now owns 8,884,263 shares of the company’s stock worth $20,256,000 after buying an additional 5,626,624 shares during the period. Bain Capital Life Sciences Investors LLC lifted its holdings in shares of Savara by 20.8% in the 1st quarter. Bain Capital Life Sciences Investors LLC now owns 17,600,621 shares of the company’s stock worth $48,754,000 after acquiring an additional 3,035,164 shares during the last quarter. Frazier Life Sciences Management L.P. boosted its position in shares of Savara by 32.4% during the 1st quarter. Frazier Life Sciences Management L.P. now owns 11,462,301 shares of the company’s stock worth $31,751,000 after purchasing an additional 2,801,922 shares during the period. Rosalind Advisors Inc. boosted its position in shares of Savara by 50.7% during the 3rd quarter. Rosalind Advisors Inc. now owns 4,000,000 shares of the company’s stock worth $14,280,000 after purchasing an additional 1,345,056 shares during the period. Finally, Nantahala Capital Management LLC raised its position in Savara by 7.3% in the first quarter. Nantahala Capital Management LLC now owns 8,075,375 shares of the company’s stock valued at $22,369,000 after purchasing an additional 550,116 shares during the period. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.